Systemische AL-Amyloidose: Klinischer Verlauf und Grenzen der Melphalan-Therapie

Abstract

We do not see an absolute indication for chemotherapy. The unfavorable prognosis--14 patients died an average of 13 months after diagnosis--requires a particularly careful consideration of potential benefits and possible risks accompanying cytostatic therapy.